
Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients. Single‐dose and double‐dose ivermectin early treatment was not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID‐19.
Like
Save
Share